Medifast Q3 2026 Earnings Call: Revenue Drop as Metabolic Health Transition Begins

Medifast reports 19.4% revenue decline in Q3 2026 as it shifts from weight management to metabolic health business model.

20 cards · 2m · tap to begin

From · · · 2m

Medifast Q3 2026 Earnings Call: Revenue Drop as Metabolic Health Transition Begins

Medifast reports 19.4% revenue decline in Q3 2026 as it shifts from weight management to metabolic health business model.

In brief

Medifast reports 19.4% revenue decline in Q3 2026 as it shifts from weight management to metabolic health business model. Medifast's Q3 revenue fell 19.4% to $72 million as it transitions to metabolic health business model with 10,200 active coaches. Originally reported by The Motley Fool.

Q3 Revenue Decline

Revenue fell 19.4% to $72 million, down from $89.7 million in Q3 2025.

Active Earning Coaches

10,200 active earning coaches, a 47.7% decrease from 19,500 in Q3 2025.

Average Revenue Per Coach

Average revenue per coach grew 54.1% to $7,064.

Net Loss

Reported net loss of $17.5 million, or $1.57 per diluted share.

Adjusted Net Loss

Adjusted net loss of $2.1 million, or $0.19 per diluted share.

Catalyst Restructuring Charges

$15.4 million in restructuring charges, including $1.6 million in cost of sales and $13.8 million in SG&A.

Cash and Investments

Cash and investment securities at $172.5 million with debt-free balance sheet.

Gross Profit

Gross profit of $50 million with 69.5% margin.

Adjusted Gross Margin

Adjusted gross margin of 71.7%, up 220 basis points.

SG&A Expense

SG&A expense increased 4.8% to $69.4 million.

Adjusted SG&A

Adjusted SG&A of $55.6 million, 77.2% of revenue.

Q4 Revenue Guidance

Q4 revenue guidance: $55 million to $75 million.

Q4 Earnings Guidance

Q4 earnings guidance: $0.00 to $0.25 per share.

Full Year Revenue Guidance

Full year revenue guidance: $280 million to $300 million.

Full Year Loss Guidance

Full year loss guidance: $1.80 to $2.05 per share.

Adjusted EBITDA

Adjusted EBITDA of $1.9 million, up 9.7% from $1.7 million.

Product Adoption

95% of active earning coaches offered Trilivy Reset line by end of Sept.

Clinical Performance

14% reduction in visceral fat while retaining 98% of lean mass over 16 weeks.

Market Opportunity

90% of U.S. adults metabolically unhealthy, $12 trillion metabolic health market.

Q4 Profitability Target

Targeting return to profitability in Q4 2026.

What it means

Medifast's Q3 revenue fell 19.4% to $72 million as it transitions to metabolic health business model with 10,200 active coaches.

Read the original on The Motley Fool

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on medifast and related topics.